Collin Regan

Collin Regan is an experienced pharmaceutical professional currently serving as a Director at Crinetics Pharmaceuticals since September 2024. Prior to this role, Regan has been a Principal Investigator at Neurocrine Biosciences since February 2013 and held various positions including Scientist and Temporary Research Scientist at Vertex and BroadPharm, respectively. Previous experience includes working at Cylene Pharmaceuticals as a Scientist, where Regan focused on small molecule inhibitors for oncology and inflammation, and also contributed to the development of novel heterocyclic scaffolds. Regan began their career at Neurocrine Biosciences as an Associate Scientist, specializing in small molecules for G-protein coupled receptors. Educational credentials include a Ph.D. in Organic Chemistry from UCLA and a B.S. in Chemistry from UC Santa Barbara.